The future of healthcare is an organic blend of technology, innovation, and human connection. As artificial intelligence (AI) is gradually becoming a go-to technology in healthcare to improve efficiency and outcomes, we must understand our limitations. We should realize that our goal is not only to provide faster and more efficient care, but also to deliver an integrated solution to ensure that the care is fair and not biased to a group of sub-population. In this context, the field of cardio-cerebrovascular diseases, which encompasses a wide range of conditions—from heart failure to stroke—has made some advances to provide assistive tools to care providers. This article aimed to provide an overall thematic review of recent development focusing on various AI applications in cardio-cerebrovascular diseases to identify gaps and potential areas of improvement. If well designed, technological engines have the potential to improve healthcare access and equitability while reducing overall costs, diagnostic errors, and disparity in a system that affects patients and providers and strives for efficiency.

Neurosarcoidosis is a rare manifestation of sarcoidosis, a systemic granulomatous disease. It presents a diagnostic challenge due to its varied clinical and radiologic features. We describe a 37-year-old male with biopsy-proven pulmonary sarcoidosis who developed progressive neurological symptoms, including dizziness, imbalance, diplopia, and lower extremity weakness. MRI revealed diffuse leptomeningeal enhancement, cervical spinal cord lesions, and left cerebellar hemorrhage with surrounding vasogenic edema, a relatively rare finding in neurosarcoidosis. Cerebrospinal fluid (CSF) analysis showed inflammatory changes, and mediastinal lymph node biopsy confirmed non-necrotizing granulomas. The patient was treated with high-dose corticosteroids followed by immunosuppressive therapy, leading to gradual improvement in gait and strength. This case highlights the importance of recognizing neurosarcoidosis as a potential cause of central nervous system hemorrhage. Cerebrovascular involvement, particularly intracerebral hemorrhage, is underrecognized but can have serious consequences, making early diagnosis and aggressive immunosuppressive therapy critical in preventing long-term neurological deficits.

Background, objective, and methods: Antiphospholipid syndrome (APS) is classically regarded as a cause of thrombosis and stroke in younger patients and is often considered a rare etiology beyond the sixth decade. We retrospectively describe seven older adults (ages 67-90 years; median 76; four females) with ischemic stroke in whom antiphospholipid antibodies (aPL) were identified during evaluation, most after one or more cerebrovascular events. Results: Six of the seven had radiographic or clinical evidence of prior cerebrovascular disease, and several had experienced recurrent events despite antiplatelet or anticoagulant therapy. Antibody profiles were heterogeneous, ranging from triple positivity with confirmed persistence to isolated lupus anticoagulant and IgM-only positivity, and competing stroke mechanisms (patent foramen ovale, large-artery atherosclerosis, and small-vessel disease) were frequently present. All patients were transitioned to a vitamin K antagonist. Conclusions: This series illustrates that aPL-associated stroke does occur in older adults and supports considering APS in the differential of cryptogenic or recurrent ischemic stroke in this population, while underscoring the need for high-specificity, persistently confirmed testing before committing a patient to lifelong anticoagulation.